The Impact of Tumor Infiltrating Lymphocytes Densities and Ki67 Index on Residual Breast Cancer Burden following Neoadjuvant Chemotherapy

Table 3

Association count (%) between TIL and PCR in the 2 molecular subtypes among 153 breast cancer cases (chi-square test).

Luminal, HER2-ve subtype	Posttherapy groups		value
	PCR group	Non-PCR group
	Count (%)	Count (%)
Lymphocyte groups
Lymphocyte poor	0 (0.0%)	16 (21.6%)	1
Intermediate group	1 (50.0%)	38 (51.4%)
Lymphocytic predominant	1 (50.0%)	20 (27.0%)
TN+ subtype
Lymphocyte groups
Lymphocyte poor	4 (14.8%)	7 (14.0%)	0.803
Intermediate group	8 (29.6%)	19 (38.0%)
Lymphocytic predominant	15 (55.6%)	24 (48.0%)

denotes statistically significant. + TNBC: triple negative subtype.